{"id":218618,"date":"2025-07-24T04:26:35","date_gmt":"2025-07-24T09:26:35","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/07\/patients-own-autoantibodies-may-hold-key-to-boosting-cancer-immunotherapy-response"},"modified":"2025-07-24T04:26:35","modified_gmt":"2025-07-24T09:26:35","slug":"patients-own-autoantibodies-may-hold-key-to-boosting-cancer-immunotherapy-response","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/07\/patients-own-autoantibodies-may-hold-key-to-boosting-cancer-immunotherapy-response","title":{"rendered":"Patients\u2019 own autoantibodies may hold key to boosting cancer immunotherapy response"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/patients-own-autoantibodies-may-hold-key-to-boosting-cancer-immunotherapy-response.jpg\"><\/a><\/p>\n<p>A new study has revealed that autoantibodies\u2014immune proteins traditionally associated with autoimmune disease\u2014may profoundly influence how cancer patients respond to immunotherapy.<\/p>\n<p>The study, <a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09188-4\" target=\"_blank\">published<\/a> in <i>Nature<\/i>, offers a potential breakthrough in solving one of modern-day oncology\u2019s most frustrating mysteries: why checkpoint inhibitors work for some patients but not others\u2014and how we can extend their benefits to more people.<\/p>\n<p>\u201cOur analysis shows that certain naturally occurring autoantibodies can tilt the odds dramatically toward shrinking tumors,\u201d said senior author Aaron Ring, MD, Ph.D., an associate professor at Fred Hutch Cancer Center. \u201cWe saw some cases where autoantibodies boosted a patient\u2019s likelihood of responding to checkpoint blockade by as much as five-to ten-fold.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new study has revealed that autoantibodies\u2014immune proteins traditionally associated with autoimmune disease\u2014may profoundly influence how cancer patients respond to immunotherapy. The study, published in Nature, offers a potential breakthrough in solving one of modern-day oncology\u2019s most frustrating mysteries: why checkpoint inhibitors work for some patients but not others\u2014and how we can extend their benefits [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1522],"tags":[],"class_list":["post-218618","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-innovation"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/218618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=218618"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/218618\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=218618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=218618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=218618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}